Whether ritexitinib (Lefenox) needs to be taken for a long time and its safety analysis

Ritlecitinib is an oral selective JAK3 kinase inhibitor, mainly used to treat moderate to severe alopecia areata (Alopecia Areata, AA) and other autoimmune related diseases. By selectively inhibiting the JAK3 signaling pathway, ritexitinib can reduce the attack of immune cells on hair follicles, thereby promoting hair regeneration. As a targeted immunomodulatory drug, it has a relatively quick onset of action, but disease control and efficacy maintenance still rely on continuous drug intervention.

Clinical data show that patients can observe hair regrowth or improvement in alopecia areata 4 to 12 weeks after taking ritexitinib. However, since alopecia areata is a chronic immune disease, some patients may experience recurrence or hair loss after stopping the drug. Therefore, doctors usually recommend that patients continue maintenance treatment to keep hair stable after the disease is controlled. The length of treatment should be adjusted according to individual condition, efficacy and tolerance. Some patients may require long-term or even continuous medication to maintain efficacy.

Ritexitinib was generally well tolerated, with common adverse reactions including mild to moderate upper respiratory tract infection, headache, mild gastrointestinal discomfort, and mild changes in hematological indicators. Serious adverse reactions such as increased risk of infection, cytopenias, or abnormal liver function are less likely to occur, but regular monitoring of blood routine, liver and kidney function, and infection symptoms is still required. In clinical practice, through reasonable dose adjustment and regular review, most patients can safely complete long-term treatment.

When using ritexitinib for long-term treatment, you should follow the doctor's guidance, take the medicine according to the dosage, and follow up the efficacy and safety indicators regularly. For patients with hematological abnormalities, severe infection or other obvious side effects, the dose should be adjusted or the medication should be suspended in a timely manner. Overall, ritixitinib has stable efficacy and controllable safety in the long-term treatment of alopecia areata and autoimmune-related diseases. Proper management and monitoring can maximize its therapeutic benefits while reducing potential risks.

Reference materials:https://www.drugs.com/